AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: Amgen (KANJINTI) (kanjinti.com)
KANJINTI avoids most corporate bullshit by leaning heavily on its regulatory ‘biosimilar’ status, which requires high-fidelity data. The BS detected is primarily ‘corporate polish’—generic headings and missing technical SEO identity markers (schema) rather than deceptive performance claims. It is a highly credible pharmaceutical resource with minor trust-theatre issues regarding review transparency.
Implement Organization and Physician/MedicalEntity JSON-LD schema to bridge the technical authority gap. Replace generic H2 headings like ‘Commitment’ and ‘Support’ with data-driven alternatives like ‘Global Supply Chain Metrics’ and ‘Patient Financial Assistance Outcomes.’ Provide direct outbound links to ClinicalTrials.gov for the LILAC study and other cited pharmacokinetic studies rather than relying on superscript footnoting. Remove the single unverified patient review to eliminate the trust theatre flag.
The site exhibits a high density of technical substance, citing specific vial sizes (150 mg and 420 mg), the chemical name (trastuzumab-anns), and specific clinical trial data like the LILAC study. However, information density is diluted by fluff headings such as ‘AMGEN OFFERS PERSONALIZED SUPPORT’ and ‘EXPERTISE’ which lack immediate specificity. The body text balances this with hard data points, such as ’40+ Years experience’ and ‘zero supply shortages,’ resulting in a relatively low BS score for this pillar.
Weak or disconnected schema makes your brand invisible in AI driven retrieval. Generate your Structured Data Audit and quantify the trust, visibility, and ranking loss caused by semantic gaps.
There is virtually zero semantic drift between the homepage and sub-pages. The homepage H1 promises support and biosimilarity, and the sub-pages deliver granular details on dosing, manufacturing quality checks (300+), and patient resources. The transition from the hero claim ‘Sets a Rigorous Standard’ to the technical ‘Identical Dosing’ page is logically consistent and scientifically supported.
Identify the current state and friction diagnosis of your specific business model. Generate your Executive SEO Strategy to quantify the financial or conversion cost of strategic misalignment.
While the site provides deep clinical context, it triggers trust theatre flags due to a ‘review_count’ of 1 on the Patient Resources page with a ‘proof_links_count’ of 0. Performance claims like ‘incredible track record’ and ‘leadership in biosimilars’ are internally cited via superscript but lack direct outbound links to peer-reviewed repositories or independent 3rd-party audits within the metadata. The reliance on internal ‘Expertise’ branding without external verification links creates a moderate proof gap.
The proof density is high for the pharmaceutical industry, with nearly every paragraph featuring superscript citations to clinical data or IQVIA analytics link data. The site demonstrates substance through technical specifications such as MUGA and ECHO scan requirements for heart monitoring. The ratio of vague assertions to verifiable technical protocols is approximately 1:4, indicating a substance-heavy presentation.
To examine how structural entropy affects chunking and retrieval, review the Moz Semantic HTML audit. View the Moz Semantic HTML Audit for a complete example of heading logic, landmark integrity, and DOM depth diagnostics.
The site uses several industry clichés such as ‘Heritage,’ ‘Commitment,’ and ‘Support’ as primary navigation/header anchors, which are common across the big-pharma sector. The value proposition of being ‘as effective as Herceptin’ is a regulatory baseline for biosimilars rather than a unique market differentiator. Despite this, the inclusion of specific manufacturing metrics (300+ quality checks) prevents it from feeling like a pure commodity template.
A significant technical authority gap exists as the site contains null schema_json data across all pages, failing to utilize Organization or Drug schema to verify its entity status. Furthermore, while it mentions ‘Amgen Oncology representatives,’ it lacks named medical experts or Person schema for its leadership, relying entirely on corporate brand authority. This lack of structured digital identity contrasts with the high-stakes nature of the medical claims being made.
The performance claims are largely grounded in regulatory approval (‘FDA approved with highly similar safety and efficacy’), which minimizes the disconnect. The only notable fluff-to-fact gap is the claim of ‘personalized support,’ which leads to standard downloadable PDFs and generic contact forms rather than evidence of a truly personalized experience. Most other claims, like ‘zero supply shortages,’ are stated as historical facts rather than future-looking marketing fluff.
Medical Devices, Pharma & Biotech BS: Amgen (KANJINTI) (kanjinti.com)
The site content perfectly aligns with the Pharma & Biotech category, focusing on biosimilarity, clinical trial equivalence (LILAC study), and FDA-approved indications. It adheres strictly to regulatory communication standards, including required Boxed Warnings and Important Safety Information (ISI).
Before embeddings, before entities, before retrieval — the crawler must reach the text. Open the Crawlability & Indexation Guide to learn how access failures erase meaning long before interpretation begins.
“The score of 38 is driven primarily by technical omissions (Identity and Authority) and 'Trust Theatre' markers (unverified reviews/lack of outbound links). The site scored exceptionally well in Semantic Coherence, showing no drift between marketing promises and technical delivery. The Information Density score reflects a healthy balance of corporate branding and medical specifications.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 31, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Amgen (KANJINTI) to view the most current version of their content and see directly what the company offers.